000661 长春高新
已收盘 06-05 15:00:00
资讯
新帖
简况
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
证券之星 · 06-05 16:42
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
证券之星 · 06-05 11:39
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
长春高新:公司长期坚持合规为先的营销管理原则
证券之星 · 06-05 11:39
长春高新:公司长期坚持合规为先的营销管理原则
长春高新:相关股东自持有公司股份以来并未减持过公司股份
证券之星 · 06-04
长春高新:相关股东自持有公司股份以来并未减持过公司股份
长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景
证券之星 · 06-04
长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景
长春高新:公司相关费用的投入本质都是构建多元管线的必要投资
证券之星 · 06-04
长春高新:公司相关费用的投入本质都是构建多元管线的必要投资
长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向
证券之星 · 06-04
长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向
长春高新:研发持续落地多款新药、核心产品市占率领先
证券之星 · 06-04
长春高新:研发持续落地多款新药、核心产品市占率领先
长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准
智通财经 · 06-03
长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准
长春高新:管理层正多措并举改善经营基本面
证券之星 · 06-03
长春高新:管理层正多措并举改善经营基本面
长春高新:销售费用为全品类产品综合员工薪酬、差旅、会议、推广投入等
证券之星 · 06-03
长春高新:销售费用为全品类产品综合员工薪酬、差旅、会议、推广投入等
长春高新:未发现违规变相协助大股东化债
证券之星 · 06-03
长春高新:未发现违规变相协助大股东化债
长春高新:公司母公司层面截止2025年末的人数为51人
证券之星 · 06-03
长春高新:公司母公司层面截止2025年末的人数为51人
长春高新:ASCO会议属于肿瘤领域相关会议
证券之星 · 06-03
长春高新:ASCO会议属于肿瘤领域相关会议
停水通知!涉及长春这些区域
市场资讯 · 06-01
停水通知!涉及长春这些区域
长春高新(000661.SZ)子公司注射用GenSci136境外生产药品注册临床试验申请获批准
智通财经 · 06-01
长春高新(000661.SZ)子公司注射用GenSci136境外生产药品注册临床试验申请获批准
股市必读:长春高新(000661)5月29日董秘有最新回复
证券之星 · 06-01
股市必读:长春高新(000661)5月29日董秘有最新回复
长春高新最新公告:甲磺酸亮丙瑞林注射液(6M)上市申请获得受理
证券之星 · 05-29
长春高新最新公告:甲磺酸亮丙瑞林注射液(6M)上市申请获得受理
长春高新(000661)披露子公司GenSci144片临床试验申请获批公告,5月26日股价下跌2.51%
证券之星 · 05-26
长春高新(000661)披露子公司GenSci144片临床试验申请获批公告,5月26日股价下跌2.51%
长春高新最新公告:子公司GenSci144片临床试验申请获批准
证券之星 · 05-26
长春高新最新公告:子公司GenSci144片临床试验申请获批准
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":68.43,"timestamp":1780642998000,"preClose":68.1,"halted":0,"volume":5370853,"delay":0,"changeRate":0.0048,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":0.33,"latestTime":"06-05 15:00:00","open":69.37,"high":69.77,"low":68.12,"amount":370000000,"amplitude":0.0242,"askPrice":68.43,"askSize":70,"bidPrice":68.42,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":68.1,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":74.91,"lowLimit":61.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.25,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":0.105556,"marketValue":27915000000,"turnoverRate":0.0134,"status":0,"floatMarketCap":27346000000},"requestUrl":"/m/hq/s/000661/wiki","defaultTab":"wiki","newsList":[{"id":"2641668116","title":"长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641668116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641668116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648935,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月05日在投资者关系平台上答复投资者关心的问题。(长春高新回复:您好,创新药从临床、准入、学术推广到真正放量,普遍需要多年培育期,必须持续投入才能形成壁垒。目前公司正处于从单一爆品向多元化创新的研发转型阵痛期,我们希望随着相关创新药后续逐步落地,能够使公司收获更多的研发成果,我们也将持续关注研发进展及费用支出情况,努力提升研发效率等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","000661","BK0188","BK0239","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194819","title":"长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194819?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:39","pubTimestamp":1780630764,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司去年计划在港交所上市,目前是什么情况呢?是计划已经取消,还是在持续推进?长春高新回复:您好,公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期。公司将结合自身经营状况、监管政策要求及市场投资者关切,审慎、合理推进后续相关工作,具体时间需要结合工作进度和监管部门审核情况。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","000661","BK0239","BK0057","BK0188","BK0028","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194848","title":"长春高新:公司长期坚持合规为先的营销管理原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194848?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:39","pubTimestamp":1780630759,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月05日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0046","BK0188","BK0075","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640582150","title":"长春高新:相关股东自持有公司股份以来并未减持过公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640582150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640582150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:48","pubTimestamp":1780577315,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:目前投资者都在担忧王思勉女士后续减持问题,请问公司如何打消投资者顾虑?长春高新回复:您好,相关股东自持有公司股份以来并未减持过公司股份;同时根据监管要求,上市公司持有百分之五以上股份的股东计划通过证券交易所集中竞价交易或者大宗交易方式减持股份的,应当在首次卖出前十五个交易日向证券交易所报告并披露减持计划;截至目前,公司未收到股东的减持计划通知。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400039301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0057","BK0188","BK0075","BK0046","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391611","title":"长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391611?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:35","pubTimestamp":1780544129,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司管理层90%都是地产行业出身,缺少专业性,这是否也导致了公司研发销售管理效率全行业最低?长春高新回复:您好,相关表述与实际不符。公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景,各医药子公司经营、研发核心团队汇聚大批深耕生物医药领域的专业人才,适配整体经营管理需求,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","09939","000661","BK1574","159940","BK0188","159938","BK1515","BK0057","BK0046","BK1161","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640139917","title":"长春高新:公司相关费用的投入本质都是构建多元管线的必要投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2640139917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640139917?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:35","pubTimestamp":1780544120,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月04日在投资者关系平台上答复投资者关心的问题。公司相关费用的投入本质都是构建多元管线的必要投资,细分包括员工薪酬、差旅、会议、推广投入等,具体费用明细请参见定期报告第八节中销售费用明细相关内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0057","BK0075","BK0028","BK0188","BK0046","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133992","title":"长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133992?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:12","pubTimestamp":1780535536,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月04日在投资者关系平台上答复投资者关心的问题。研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向。公司已建立全流程研发费用管控、决策机制和内控体系,努力保障每一笔研发资金合理、合规使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0046","BK0075","BK0028","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133647","title":"长春高新:研发持续落地多款新药、核心产品市占率领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133647","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133647?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:09","pubTimestamp":1780535373,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:公司研发、销售、管理方面的能力什么时候能够达到专业医药公司的水平?目前公司的研发销售管理完全就是一个业余水平,投入巨大,毫无成效。 这种状况何时能够改善?长春高新回复:您好,公司深耕生物医药多年,研发持续落地多款新药、核心产品市占率领先,搭建完备研产销体系。目前正努力克服政策及行业变化影响,持续优化投入效率与内部管理,稳步提质增效,公司也希望相关改善成效随项目落地逐步体现。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0239","BK0028","BK0075","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890809","title":"长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640890809?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:53","pubTimestamp":1780480433,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci155注射液境内生产药品注册临床试验申请获得批准。GenSci155注射液是金赛药业自主研发的一款长效化脂肪酸偶联重组人胰岛素样生长因子-1(IGF-1)类似物,注册分类为治疗用生物制品1类,拟用于预防早产儿支气管肺发育不良(BPD)、急性缺血性卒中(AIS)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000661","BK0057","BK0028","BK0075","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640774919","title":"长春高新:管理层正多措并举改善经营基本面","url":"https://stock-news.laohu8.com/highlight/detail?id=2640774919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640774919?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:51","pubTimestamp":1780476685,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:”集团总部承担战略管控、投融资、合规风控、资本运作、子公司统筹赋能等集团化必备职能”,这是公司对于总部的职能的回复,那么在公司股价和净利润均创下十年新低的情况下,公司的管理层到底起到了什么具体的正向作用呢?长春高新回复:您好,业绩与股价受行业政策、市场环境等多重外部因素影响,管理层正多措并举改善经营基本面,全力提振经营效益。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","BK0046","BK0239","000661","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640774089","title":"长春高新:销售费用为全品类产品综合员工薪酬、差旅、会议、推广投入等","url":"https://stock-news.laohu8.com/highlight/detail?id=2640774089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640774089?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:51","pubTimestamp":1780476684,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月03日在投资者关系平台上答复投资者关心的问题。销售费用为全品类产品综合员工薪酬、差旅、会议、推广投入等,并非仅对应两款新品;新品尚处在上市导入期,短期营收偏低属行业常态,费用经审计合规列支,不存在利益输送情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0075","000661","BK0239","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640019972","title":"长春高新:未发现违规变相协助大股东化债","url":"https://stock-news.laohu8.com/highlight/detail?id=2640019972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640019972?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475265,"startTime":"0","endTime":"0","summary":"生长激素属处方药,仍需要合理销售投入,是生物制药行业通用经营投入逻辑;研发资金单独核算、按项目归集,会计准则与监管制度严格限定费用使用范围;公司及会计师年审也会关注核验成本归集真实性及与大股东之间的资金往来情况,未发现存在违规变相协助大股东化债的情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0239","BK0046","BK0057","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640726969","title":"长春高新:公司母公司层面截止2025年末的人数为51人","url":"https://stock-news.laohu8.com/highlight/detail?id=2640726969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640726969?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:06","pubTimestamp":1780473977,"startTime":"0","endTime":"0","summary":"投资者提问:对比2025年报合并万余名在职员工与母公司极低社保参保人数,二者数据严重脱节。要求管理层拆分全部用工类型人数,汇总所有子公司参保明细,阐释巨额人数差的全部来源。长春高新回复:您好,上市公司信息披露需按照法律法规要求进行,公司母公司层面截止2025年末的人数为51人,其余员工人数均为子公司相关,上市公司员工情况请查阅年度报告-公司员工情况相关章节内容,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300030654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0239","BK0057","BK0075","BK0028","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640370972","title":"长春高新:ASCO会议属于肿瘤领域相关会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2640370972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640370972?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:00","pubTimestamp":1780473650,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:2026ASCO会议中国真创新药企业均提交了大量的研究成果,为什么贵公司没有参加呢?是没有成果吗?长春高新回复:您好,公司会结合实际经营需要、研发管线现状、对外合作意向等积极参加符合公司实际经营需要的会议,ASCO会议属于肿瘤领域相关会议,目前公司在肿瘤领域相关创新管线部分处于I期临床阶段,相关重要临床数据读出还需一定时间,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300030017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0075","000661","BK0239","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640956130","title":"停水通知!涉及长春这些区域","url":"https://stock-news.laohu8.com/highlight/detail?id=2640956130","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640956130?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:04","pubTimestamp":1780311840,"startTime":"0","endTime":"0","summary":"(来源:长春相遇)刚刚,长春水务发展集团有限公司发布停水通知,详情如下:\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzxewn3870782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0057","000661","BK0046","BK0075","BK0188","BK0239","BK0028","SINA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640301629","title":"长春高新(000661.SZ)子公司注射用GenSci136境外生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640301629","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640301629?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:43","pubTimestamp":1780306991,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到美国食品药品监督管理局关于同意GenSci136开展临床试验的批准文件。据悉,注射用GenSci136是金赛药业自主研发的一款B细胞成熟抗原(BCMA)三聚体融合蛋白,BAFF/APRIL双靶点拮抗剂,美国新药注册类别351(a)BLA,属治疗用生物制品1类药物,拟用于治疗重症肌无力(MG)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)子公司注射用GenSci136境外生产药品注册临床试验申请获批准","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","000661","BK0188","BK0046","BK0057","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640478983","title":"股市必读:长春高新(000661)5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640478983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640478983?lang=zh_cn&edition=full","pubTime":"2026-06-01 01:54","pubTimestamp":1780250054,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,长春高新报收于73.57元,上涨0.78%,换手率2.19%,成交量8.77万手,成交额6.46亿元。还是主动终止临床试验的成人生长激素缺乏症项目没有资本化金额?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100000811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0239","BK0046","BK0057","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639265746","title":"长春高新最新公告:甲磺酸亮丙瑞林注射液(6M)上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2639265746","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639265746?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:52","pubTimestamp":1780048333,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》,甲磺酸亮丙瑞林注射液(6M)用于乳腺癌治疗的上市申请获得受理。该产品为长效皮下注射制剂,给药间隔延长至6个月,可减少患者注射频率。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900033335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","BK0046","BK0239","000661","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638954801","title":"长春高新(000661)披露子公司GenSci144片临床试验申请获批公告,5月26日股价下跌2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638954801","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638954801?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:21","pubTimestamp":1779805273,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘,长春高新报收于77.76元,较前一交易日下跌2.51%,最新总市值为317.21亿元。近日,长春高新技术产业(集团)股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,GenSci144片境内生产药品注册临床试验申请获得批准,拟用于苯丙酮尿症治疗。GenSci144片为金赛药业自主研发的口服小分子抑制剂,作用机制为抑制SLC6A19介导的苯丙氨酸重吸收,不依赖PAH酶活性,适用于更广泛PKU患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0239","BK0028","BK0075","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638908335","title":"长春高新最新公告:子公司GenSci144片临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2638908335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638908335?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:16","pubTimestamp":1779786962,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》,GenSci144片境内生产药品注册临床试验申请获得批准,拟用于苯丙酮尿症(PKU)的治疗。该药品为口服小分子抑制剂,可降低血苯丙氨酸水平,为PKU患者提供新治疗选择。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600028880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000661","BK0239","BK0057","BK0188","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780870233596,"stockEarnings":[{"period":"1week","weight":-0.0699},{"period":"1month","weight":-0.197},{"period":"3month","weight":-0.2459},{"period":"6month","weight":-0.3125},{"period":"1year","weight":-0.3316},{"period":"ytd","weight":-0.2591}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}